NCT06767956 2026-04-13
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
Phase 1/2 Withdrawn
University of Pittsburgh
University of Utah
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham